Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
|---|---|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2025 |
May 31, 2024 |
|
| Related Party Transaction [Line Items] | ||||
| Research and development expense | $ 70,873 | $ 10,130 | ||
| Accrued expenses | 46,714 | $ 37,836 | ||
| Hengrui License Agreement | ||||
| Related Party Transaction [Line Items] | ||||
| Research and development expense | 400 | $ 400 | ||
| Accrued expenses | $ 600 | $ 200 | ||
| Hengrui License Agreement | Series A-2 Convertible Preferred Stock | ||||
| Related Party Transaction [Line Items] | ||||
| Shares issued as a percentage of outstanding capital stock | 19.90% | |||
| X | ||||||||||
- Definition Percentage of capital stock issued. No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|